FDA-Approved GLP-1 Drugs Offer Obesity Option for U.S. Adolescents 12+ as 1 in 5 Children Are Affected
Updated
Updated · Loma Linda University · Aug 17
FDA-Approved GLP-1 Drugs Offer Obesity Option for U.S. Adolescents 12+ as 1 in 5 Children Are Affected
3 articles · Updated · Loma Linda University · Aug 17
Summary
Certain GLP-1 receptor agonists are FDA-approved for chronic weight management in adolescents 12 and older with obesity, a pediatric endocrinologist said, but only as an added tool when diet and exercise alone fall short.
GLP-1 drugs mimic a hormone that regulates appetite, blood sugar and digestion, helping patients feel full sooner and potentially lose weight while improving obesity-related conditions.
Type 2 diabetes, fatty liver disease, sleep apnea and PCOS are among the risks that weight reduction may help ease, with doctors also citing gains in mobility, activity and self-image.
Nausea, stomach pain, constipation and diarrhea are common side effects, while rarer serious risks and limited long-term pediatric data mean the drugs should be prescribed and closely monitored within a broader treatment plan.
About 1 in 5 U.S. children and adolescents have obesity, underscoring why parents are increasingly asking whether newer GLP-1 medicines are appropriate for younger patients.